Letter to the Editor

Abstract

To the Editor—I have read with interest the article
by Weinstein et al. “Modeling for Health Care
and Other Policy Decisions: Uses, Roles, and Validity.”
I agree with the authors that this is a controversial
area, but I am not sure that the authors
have considered what I would see as the fundamental
questions in this debate: Who are the endusers
of “modeled” cost-effectiveness claims and
what are their information needs? Indeed, should
the focus of pharmacoeconomics be on making
recommendations as to the cost-effective use of
medical technologies, or should we be looking at
the wider picture?